PLIANT THERAPEUTICS INC (PLRX) Fundamental Analysis & Valuation

NASDAQ:PLRX • US7291391057

Current stock price

1.19 USD
-0.02 (-1.65%)
Last:

This PLRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PLRX Profitability Analysis

1.1 Basic Checks

  • In the past year PLRX has reported negative net income.
  • In the past year PLRX has reported a negative cash flow from operations.
  • PLRX had negative earnings in each of the past 5 years.
  • PLRX had a negative operating cash flow in each of the past 5 years.
PLRX Yearly Net Income VS EBIT VS OCF VS FCFPLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -69.03%, PLRX is doing worse than 75.39% of the companies in the same industry.
  • PLRX's Return On Equity of -94.04% is on the low side compared to the rest of the industry. PLRX is outperformed by 65.97% of its industry peers.
Industry RankSector Rank
ROA -69.03%
ROE -94.04%
ROIC N/A
ROA(3y)-50.26%
ROA(5y)-45.99%
ROE(3y)-61.88%
ROE(5y)-54.77%
ROIC(3y)N/A
ROIC(5y)N/A
PLRX Yearly ROA, ROE, ROICPLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • PLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLRX Yearly Profit, Operating, Gross MarginsPLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. PLRX Health Analysis

2.1 Basic Checks

  • PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PLRX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PLRX has been increased compared to 5 years ago.
  • There is no outstanding debt for PLRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PLRX Yearly Shares OutstandingPLRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
PLRX Yearly Total Debt VS Total AssetsPLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • PLRX has an Altman-Z score of -4.61. This is a bad value and indicates that PLRX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -4.61, PLRX is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.14 indicates that PLRX is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.14, PLRX is in line with its industry, outperforming 43.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -4.61
ROIC/WACCN/A
WACC10.04%
PLRX Yearly LT Debt VS Equity VS FCFPLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • PLRX has a Current Ratio of 12.99. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
  • PLRX has a Current ratio of 12.99. This is amongst the best in the industry. PLRX outperforms 84.82% of its industry peers.
  • PLRX has a Quick Ratio of 12.99. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of PLRX (12.99) is better than 84.82% of its industry peers.
Industry RankSector Rank
Current Ratio 12.99
Quick Ratio 12.99
PLRX Yearly Current Assets VS Current LiabilitesPLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PLRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.68% over the past year.
EPS 1Y (TTM)29.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PLRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.53% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.02%
EPS Next 2Y22.55%
EPS Next 3Y13.38%
EPS Next 5Y9.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLRX Yearly Revenue VS EstimatesPLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2029 2030 2031 2032 2033 50M 100M 150M
PLRX Yearly EPS VS EstimatesPLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. PLRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PLRX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLRX Price Earnings VS Forward Price EarningsPLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLRX Per share dataPLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PLRX's earnings are expected to grow with 13.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.55%
EPS Next 3Y13.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PLRX Dividend Analysis

5.1 Amount

  • PLRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PLRX Fundamentals: All Metrics, Ratios and Statistics

PLIANT THERAPEUTICS INC

NASDAQ:PLRX (4/29/2026, 2:31:21 PM)

1.19

-0.02 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.22
Industry Growth16.77
Earnings (Last)03-11
Earnings (Next)05-11
Inst Owners76.92%
Inst Owner Change0%
Ins Owners1.75%
Ins Owner Change-1.66%
Market Cap73.67M
Revenue(TTM)N/A
Net Income(TTM)-206.96M
Analysts50.91
Price Target2.72 (128.57%)
Short Float %6.03%
Short Ratio6.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.31%
Min EPS beat(2)-24.53%
Max EPS beat(2)-0.1%
EPS beat(4)2
Avg EPS beat(4)-0.63%
Min EPS beat(4)-24.53%
Max EPS beat(4)18.2%
EPS beat(8)5
Avg EPS beat(8)2.55%
EPS beat(12)8
Avg EPS beat(12)3.26%
EPS beat(16)10
Avg EPS beat(16)2.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.95%
PT rev (3m)-17.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)39.46%
EPS NY rev (3m)39.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-2.76
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0
BVpS3.55
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -69.03%
ROE -94.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.26%
ROA(5y)-45.99%
ROE(3y)-61.88%
ROE(5y)-54.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.99
Quick Ratio 12.99
Altman-Z -4.61
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)84.39%
Cap/Depr(5y)95.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.66%
EPS Next Y37.02%
EPS Next 2Y22.55%
EPS Next 3Y13.38%
EPS Next 5Y9.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.75%
OCF growth 3YN/A
OCF growth 5YN/A

PLIANT THERAPEUTICS INC / PLRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PLIANT THERAPEUTICS INC (PLRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to PLRX.


What is the valuation status of PLIANT THERAPEUTICS INC (PLRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to PLIANT THERAPEUTICS INC (PLRX). This can be considered as Overvalued.


How profitable is PLIANT THERAPEUTICS INC (PLRX) stock?

PLIANT THERAPEUTICS INC (PLRX) has a profitability rating of 0 / 10.


What is the expected EPS growth for PLIANT THERAPEUTICS INC (PLRX) stock?

The Earnings per Share (EPS) of PLIANT THERAPEUTICS INC (PLRX) is expected to grow by 37.02% in the next year.